Anaplastic Large Cell Lymphoma With Intraocular or Ocular Adnexal Involvement: A Case Report and Systematic Review

医学 间变性大细胞淋巴瘤 布仑妥昔单抗维多汀 CD30 淋巴瘤 间变性淋巴瘤激酶 外科 皮肤病科 内科学 恶性胸腔积液 胸腔积液
作者
Seyed Mohsen Rafizadeh,Hossein Ghahvehchian,Mohammad Taher Rajabi,Mostafa Heidari,Elaham Rahmanikhah
出处
期刊:Ophthalmic Plastic and Reconstructive Surgery [Ovid Technologies (Wolters Kluwer)]
标识
DOI:10.1097/iop.0000000000002520
摘要

To review the existing literature on patients with anaplastic large cell lymphoma (ALCL) affecting the globe and/or ocular adnexa, and to present a report documenting the clinical course of a patient with ALCL that involved their globe and ocular adnexa.PubMed, Scopus, and Google scholar were systematically searched for all cases of ALCL involving intraocular or adnexal ocular structures from inception to May 2023. Moreover, a new reported case added to the cases found in searches.The review identified 1680 studies, with 8 meeting inclusion criteria. A total of 9 patients were included with a mean age of 29.7 years (median: 30.0, range: 1.3-48). Primary ALCL was present in 5/9 (55.6%) patients. The most common ophthalmic manifestations included periorbital swelling (5/8), chemosis (5.8), and decreased vision (5/7). Misdiagnoses were initially made in 3 patients, and the lag time to correct diagnosis from 3 weeks to 3 months. CD30 expression was positive in all cases, and 6/9 patients were positive for anaplastic lymphoma kinase, resulting in 6/9 patients being diagnosed with anaplastic lymphoma kinase-positive ALCL. In terms of management modalities, chemotherapy was administered in 8/9 patients, while radiation therapy was utilized in 4/9 patients, and 2 underwent autologous stem cell transplantation. Five (55.6%) patients succumbed to ALCL while 4 (44.4%) were alive and disease-free at the last follow-up. The median times from the initial presentation of ALCL to death, ophthalmic presentation to death, and diagnosis to death were 4.12 months (range: 1.1-168.0), 2.62 months (range: 1.1-144), and 4.00 months (range: 0.10-168), respectively. The median follow-up duration was 21.0 months (range: 1.1-168.0).ALCL involving the globe and ocular adnexa is a rare and highly malignant tumor that can mimic benign clinical conditions. Early biopsy and aggressive treatment with chemotherapy regimens such as CHOP and radiation therapy may be useful.

科研通智能强力驱动
Strongly Powered by AbleSci AI

祝大家在新的一年里科研腾飞
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Mic应助Max哈哈哈采纳,获得10
3秒前
科研通AI6.1应助Max哈哈哈采纳,获得10
3秒前
活泼盼望发布了新的文献求助10
3秒前
xsy完成签到 ,获得积分10
3秒前
SciGPT应助长苼采纳,获得30
3秒前
3秒前
腼腆小美发布了新的文献求助10
7秒前
Akim应助邓炎林采纳,获得10
7秒前
8秒前
Thanatos完成签到,获得积分10
9秒前
10秒前
灵巧幻露完成签到,获得积分10
12秒前
15秒前
17秒前
Jasper应助活泼盼望采纳,获得10
18秒前
燃燃发布了新的文献求助10
21秒前
21秒前
22秒前
MOMO完成签到,获得积分10
24秒前
jocelyn发布了新的文献求助10
26秒前
淡定的冰巧完成签到,获得积分10
27秒前
ai zs发布了新的文献求助10
27秒前
28秒前
风趣的芝麻完成签到 ,获得积分10
31秒前
CodeCraft应助zhx采纳,获得10
32秒前
tao发布了新的文献求助10
32秒前
YanDongXu完成签到 ,获得积分10
35秒前
小马甲应助cccc采纳,获得10
37秒前
共享精神应助清爽的珍采纳,获得10
38秒前
大个应助科研通管家采纳,获得10
38秒前
38秒前
大个应助科研通管家采纳,获得10
38秒前
SciGPT应助科研通管家采纳,获得10
38秒前
38秒前
39秒前
SciGPT应助科研通管家采纳,获得10
39秒前
39秒前
39秒前
852应助科研通管家采纳,获得10
39秒前
小二郎应助科研通管家采纳,获得30
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea de guyane 2500
Common Foundations of American and East Asian Modernisation: From Alexander Hamilton to Junichero Koizumi 600
Signals, Systems, and Signal Processing 510
Discrete-Time Signals and Systems 510
Competency Based Human Resource Management 500
How to Develop Robust Scale-up Strategies for Complex Injectable Dosage Forms 450
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5864091
求助须知:如何正确求助?哪些是违规求助? 6398033
关于积分的说明 15650223
捐赠科研通 4978317
什么是DOI,文献DOI怎么找? 2685323
邀请新用户注册赠送积分活动 1628409
关于科研通互助平台的介绍 1586098